Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
Naturl Alt Intl (NAII) delivers science-backed nutritional solutions through advanced manufacturing and strategic partnerships. This news hub provides investors and industry professionals with essential updates on the company's operational milestones, product innovations, and market positioning.
Access authoritative reporting on NAII's financial disclosures, regulatory achievements, and clinical research collaborations. Our curated collection includes earnings reports, manufacturing capacity expansions, patent filings, and quality assurance certifications - all critical for evaluating the company's industry leadership.
Key updates cover formulation advancements, production facility upgrades, and partnership agreements with healthcare organizations. Track NAII's progress in developing condition-specific supplements while maintaining compliance with global regulatory standards.
Bookmark this page for streamlined access to NAII's latest developments in private-label manufacturing and nutritional science. Check regularly for verified updates that matter to stakeholders in the nutraceuticals sector.
Natural Alternatives International (NAI) has unveiled TriBsyn™, a revolutionary carnosine booster under its CarnoSyn® Brands portfolio. This groundbreaking product utilizes CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia, a common side effect. TriBsyn™ improves beta-alanine absorption by more than four times compared to conventional forms, allowing for lower dosages and increased formulation flexibility.
The product aims to support general wellness, including cognitive performance, muscle function in older adults, and slowing age-related health decline. NAI plans to launch TriBsyn™ commercially at the 46th ESPEN Congress in Milan, Italy, in September. The company expects this innovation to strengthen its presence in dietary supplement categories and fortified and medical foods markets, particularly targeting the aging population and those with plant-based diets.
Natural Alternatives International (NAII) announced its fiscal 2024 Q3 results, revealing a net loss of $1.6 million, or ($0.27) per diluted share, on net sales of $25.1 million. This compares to a $2.4 million net loss in Q3 of the prior year. Q3 net sales fell by 23%, driven by a 26% decrease in private-label contract manufacturing sales. However, CarnoSyn® beta-alanine revenue rose 13% to $2.7 million. For the nine months ending March 31, 2024, NAII reported a net loss of $5.3 million on net sales of $84.3 million, a 29% decrease year-over-year. Cash reserves stood at $12.4 million, with zero outstanding on their credit facility. The company expects to report a net loss for Q4 and fiscal 2024 due to ongoing market adjustments but forecasts future sales growth and a return to profitability with the reopening of their Carlsbad facility in May 2024.
FAQ
What is the current stock price of Naturl Alt Intl (NAII)?
What is the market cap of Naturl Alt Intl (NAII)?
